Clinical Trials

Cysteamine bitartrate has been evaluated across numerous Phase 1, Phase 2, and Phase 3 clinical trials for cystinosis, alongside exploratory indications including nonalcoholic fatty liver disease, asthma, inherited mitochondrial diseases such as Leigh syndrome, major depressive disorder, and schizophrenia. Supported by diverse academic, governmental, and industrial sponsors—including Amgen, Nacuity Pharmaceuticals, the Icahn School of Medicine at Mount Sinai, and the National Institute of Diabetes and Digestive and Kidney Diseases—these investigations span completed, active, terminated, and unknown recruitment statuses.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05994534 ACTIVE_NOT_RECRUITING
Cystinosis
Nacuity Pharmaceuticals, Inc.
2023-10-29 PHASE1; PHASE2
NCT03883984 COMPLETED
Asthma
Children's Hospital Medical Center, Cincinnati
2019-06-18 PHASE1
NCT01197378 COMPLETED
Cystinosis
Amgen
2010-08-27 PHASE3
NCT02473445 TERMINATED
Mitochondrial Diseases
Amgen
2015-05-19 PHASE2
NCT01744782 COMPLETED
Cystinosis
Amgen
2012-12-20 PHASE3
NCT02012114 COMPLETED
Cystinosis
Hospices Civils de Lyon
2011-12
NCT02023866 COMPLETED
Inherited Mitochondrial Disease, Including Leigh Syndrome
Amgen
2014-05 PHASE2
NCT01529268 COMPLETED
Nonalcoholic Fatty Liver Disease (NAFLD)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2012-06 PHASE2; PHASE3
NCT01733316 COMPLETED
Cystinosis
Amgen
2013-01-31 PHASE3
NCT01139125 TERMINATED
Schizophrenia; Schizoaffective
Augusta University
2009-09
NCT01432561 COMPLETED
Cystinosis; Nephropathic Cystinosis
University of California, San Diego
2011-09
NCT01000961 COMPLETED
Cystinosis
Amgen
2010-06 PHASE3
NCT00872729 COMPLETED
Cystinosis
Amgen
2009-05 PHASE1; PHASE2
NCT00715559 TERMINATED
Major Depressive Disorder
Icahn School of Medicine at Mount Sinai
2008-07

(data from https://clinicaltrials.gov, updated on 2026-06-30)

Check the Cysteamine bitartrate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Cysteamine bitartrate acts as a cystine-depleting agent by entering lysosomes and undergoing thiol-disulfide exchange with cystine, yielding cysteine and a cysteamine-cysteine mixed disulfide capable of exiting the lysosomal membrane via intact transport mechanisms. By clearing lysosomal cystine accumulation and exerting secondary antioxidant properties, this mechanism prevents cellular toxicity and tissue deterioration in conditions such as nephropathic cystinosis and nonalcoholic fatty liver disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.